TABLE 7.

Evaluation of three 5% formulations of dendrimer SPL7013 against genital herpes in mice

TreatmentConcn (mg/ml)Time (min) treated prior to challengeFraction (%) of animals protected against:
DiseaseInfection
SPL7013 formulation 1V503010/16 (63)a10/16 (63)a
SPL7013 formulation 2V503015/16 (94)a15/16 (94)a
SPL7013 formulation 3V503016/16 (100)a16/16 (100)a
SPL7013 formulation 1V50514/16 (88)a13/16 (81)
SPL7013 formulation 2V50515/16 (94)a15/16 (94)a
SPL7013 formulation 3V50515/16 (94)a15/16 (94)a
PBS50/16 (0)0/16 (0)
  • a P < 0.001 versus PBS.